Cargando…
Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in Humans
INTRODUCTION: Ulotaront (SEP-363856), a dual trace animeassociated receptor 1 (TAAR1) and 5-HT(1A) receptor agonist, is in phase 3 clinical development for the treatment of schizophrenia. This study evaluated the comparative bioequivalence (BE) between tablet and capsule formulations of ulotaront an...
Autores principales: | Chen, Yu-Luan, Tsukada, Hironobu, Milanovic, Snezana, Shi, Lei, Li, Yan, Mao, Yongcai, Koblan, Kenneth S., Galluppi, Gerald R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195965/ https://www.ncbi.nlm.nih.gov/pubmed/36932300 http://dx.doi.org/10.1007/s40120-023-00459-8 |
Ejemplares similares
-
Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia
por: Galluppi, Gerald R., et al.
Publicado: (2021) -
In Vitro ADME and Preclinical Pharmacokinetics of Ulotaront, a TAAR1/5-HT(1A) Receptor Agonist for the Treatment of Schizophrenia
por: Xiao, Guangqing, et al.
Publicado: (2022) -
A Phase I, Open-Label, Fixed Sequence Study to Investigate the Effect of Cytochrome P450 2D6 Inhibition on the Pharmacokinetics of Ulotaront in Healthy Subjects
por: Tsukada, Hironobu, et al.
Publicado: (2023) -
A randomized, single‐dose, crossover study of the effects of ulotaront on electrocardiogram intervals in subjects with schizophrenia
por: Tsukada, Hironobu, et al.
Publicado: (2023) -
Pharmacokinetics and Bioequivalence Evaluation of Cyclobenzaprine Tablets
por: Brioschi, Tatiane Maria de Lima Souza, et al.
Publicado: (2013)